Molecular Imaging & Therapy Using Ultrasound


To develop, translate, and commercialize new ultrasound techniques for molecular imaging and therapy

Anticipated Impact: 

New ultrasound-based molecular approaches for the diagnosis and treatment of cancer and other major diseases


Ultrasound is one of the leading medical diagnostic tools in the world due to its high portability and low cost. More ultrasound procedures are performed than any other type of imaging, including X-rays, computed tomography (CT), and magnetic resonance imaging (MRI). The University of Washington (UW) and Washington companies are established leaders in biomedical ultrasound research, development, and commercialization. Ultrasound has traditionally been used for visualizing anatomical structures. However, combining ultrasound technologies with advanced molecular approaches could potentially revolutionize disease diagnosis and treatment by allowing clinicians to target specific molecules in tissues for more precise imaging as well as for delivery of drugs. The program team will create a center focused on researching, translating, and commercializing new ultrasound techniques for molecular imaging and therapy. The ultrasound-based Washington Molecular Imaging and Therapy Center (uWAMIT) will capitalize on the UW's existing expertise and initiatives as well as recruit new faculty and support novel research projects. Partnerships with clinicians, industry, and venture capitalists are anticipated to accelerate clinical translation and commercialization.

See also:

Prostate Cancer Detection, Biomarkers, Targeted Therapy
Ultrasound-Enhanced Pancreatic Cancer Therapy

Grant Update

Principal Investigator:
Thomas Matula
Grantee Organization:
University of Washington
Grant Title:
Molecular Imaging & Therapy using Ultrasound
Grant Cohort and Year:
2009 Program Grant (02)
Grant Period:
07/16/2010 - 08/31/2017 (Completed)
Grant Amount:
The core uWAMIT team has been working together for over a year now. There has been a significant amount of collaboration between the core group that includes Radiology, Bioengineering, and CIMU. Multiple proposals have been submitted that include this multi-departmental collaboration. Commercialization continues to move forward, and we are pleased to announce that our team was selected by the Coulter Foundation to engage in a commercialization workshop. We want to thank the Life Sciences Discovery Fund for their extraordinary support and assistance as we continue to grow this important research center in Washington state.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
1, 11, 34, 36, 37, 43, 46

Health Impacts

Prostate Cancer Detection, Biomarkers, Targeted Therapy
Ultrasound-Enhanced Pancreatic Cancer Therapy